Torrejon De Ardoz

• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Recruiting
  2024-518296-56-00 5 2025-09-29 Crohn’s Disease
• Study that aims to investigate how effective and safe the use of a novel modified release tablet formulation of Colesevelam hydrochloride-MM … Recruiting
  2024-511993-55-00 4 2025-09-18 bile acid diarrhoea (BAD)
• A study to test whether vicadrostat (BI 690517) in combination with empagliflozin helps people with heart failure and a weak pumping functio … Recruiting
  2024-519525-38-00 5 2025-08-22 Heart failure
• Phase I Study of PM54 Administered to Patients with Advanced Solid Tumors Recruiting
  2024-517579-19-00 3 2025-03-24 Selected Advanced Solid Tumors
• A Phase IV, Multicenter, Open-label, Single-arm Study to Evaluate the Safety of Almagate in Pregnant Women With Heartburn and Reflux, and Pe … Recruiting
  2024-515381-14-00 6 2024-11-20 heartburn and or reflux
• Beta-Blockers in Takotsubo Syndrome: A Randomized Clinical Trial Recruiting
  2023-510213-25-01 6 2024-07-08 Takotsubo Syndrome (TT) is an acute cardiac condition
• Aspirin versus placebo in twin pregnancies for preeclampsia prevention: A multicentre, randomised, double-blind, placebo-controlled trial (A … Recruiting
  2023-503698-40-00 5 2023-03-23 Preeclampsia
• Single antiplatelet treatment with Ticagrelor or Aspirin after Transcatheter Aortic Valve Implantation: multicenter randomized clinical tria … Recruiting
  2023-509290-22-00 6 2022-01-21 Severe Symptomatic Aortic Stenosis
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting
  2023-505438-85-00 5 2022-01-12 Acute myocardial infarction (AMI)
• A Clinical trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia. (EVOLU … Recruiting
  2023-507372-42-00 4 2021-09-20 Schizophrenia
• A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692 … Ended recruitment
  2024-512914-16-00 5 2025-09-12 Relapsing-remitting Multiple Sclerosis
• A dose finding study with an anti-TSLP antibody (GSK5784283) in adults aged 18 to 75 years of age with uncontrolled asthma. Ended recruitment
  2024-518321-15-00 4 2025-05-30 Asthma
• A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended recruitment
  2024-513210-36-00 5 2025-04-04 Chronic Spontaneous Urticaria
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Ended recruitment
  2023-508636-61-00 5 2024-10-24 Crohn’s Disease
• PHASE II STUDY FOR PATIENTS WITH ADVANCED TRIPLE NEGATIVE OR METAPLASTIC HRPOSITIVE/HER2-NEGATIVE, PIK3CA/PTEN-ALTERED BREAST CANCER TREATED … Ended recruitment
  2024-512963-30-00 4 2023-05-24 Locally advanced or unresectable PIK3CA and/or PTENaltered metaplastic
• Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Crohn's Disease Ended recruitment
  2023-504741-32-00 4 2022-11-30 Moderately to Severely Active Crohn's Disease
• Efficacy and Safety of Combination Therapy with Guselkumab and Golimumab in Participants with Moderately to Severely Active Ulcerative Colit … Ended recruitment
  2023-504743-13-00 4 2022-11-30 Moderately to Severely Active Ulcerative Colitis
• Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat … Ended recruitment
  2023-509372-41-00 5 2022-01-30 Multiple Sclerosis
• Randomized clinical trial assessing the value of Beta-Blockers and Antiplatelet Agents in patients with Spontaneous Coronary Artery Dissecti … Ended recruitment
  2024-516039-28-00 6 2021-09-28 Spontaneous Coronary Artery Dissection.
• Chemotherapy-Free pCR-Guided Strategy with subcutaneous trastuzumabpertuzumab and T-DM1 in HER2-positive early breast cancer (PHERGAIN-2) Ended recruitment
  2023-508738-32-00 4 2021-06-16 Previously untreated and histologically confirmed HER2-Positive (HER2
• A Study of the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease Ended recruitment
  2023-504736-18-00 10 2018-07-26 Moderately to Severely Active Crohn's Disease
• Phase 2 Study of CAL02 plus Standard of Care in Severe Community-Acquired Bacterial Pneumonia (SCABP) Halted
  2022-502049-91-00 4 2023-09-26 SEVERE COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA (SCABP)
• Dose-response characterization of VER-01 in the treatment of patients with chronic non-specific low back pain Ended
  2023-507358-34-00 4 2024-02-13 For the treatment of patients with chronic non-specific low back pain
• "Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations (MIRANDA)" Ended
  2023-505543-39-00 5 2024-02-12 Chronic Obstructive Pulmonary Disease (COPD)

Showing 25–48 of 54 trials